WANY
GLMD icon

Wealthspire Advisors (New York)’s Galmed Pharmaceuticals GLMD Stock Holding History

Wealthspire Advisors (New York)’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$29 – 1772
2025
Q3 		$29 Buy
+21
New +$34 ﹤0.01% 3031

Other funds holding GLMD

Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Wealthspire Advisors (New York)'s GLMD Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Galmed Pharmaceuticals (GLMD) in Q4 2025, closing a stake of 21 shares — an estimated $29 sold.

Wealthspire Advisors (New York) first reported a position in GLMD in Q3 2025 and held it in 1 quarter. The position peaked at $29 in Q3 2025. 17 funds tracked by Wall St. Rank hold GLMD as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Galmed Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 21 Galmed Pharmaceuticals shares in Q4 2025, an estimated $29.
  • Wealthspire Advisors (New York) first reported a position in Galmed Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Galmed Pharmaceuticals position peaked at $29 in Q3 2025.
  • 17 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.